Metronomic Maintenance Therapy in Refractory Acute Myeloblastic Leukemia with Monosomy 7

Patients with acute myeloblastic leukemia (AML) with monosomy 7 are a group of patients with refractory AML who have a very poor prognosis. Therefore، rationally designed new therapies، including metronomic chemotherapy regimen with histidine deacetylase inhibitors (Valporic acid، ATRA) are being investigated as potential treatments for the population of refractory cases of AML. Herein، we report a patient with primary refractory AML who was treated with oral low-dose chemotherapy after standard systemic chemotherapy.